These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1835223)

  • 41. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay.
    Desai M; Franklin BD; Holmes AH; Trust S; Richards M; Jacklin A; Bamford KB
    BMC Infect Dis; 2006 Jun; 6():94. PubMed ID: 16762061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of teicoplanin for enterococcal infections: 63 cases and review.
    Schmit JL
    Clin Infect Dis; 1992 Aug; 15(2):302-6. PubMed ID: 1387808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A clinical trial on efficacy and safety of teicoplanin in combination with beta-lactams and aminoglycosides in the treatment of severe sepsis of patients undergoing allogeneic/autologous bone marrow transplantation.
    Lang E; Schmid J; Fauser AA
    Br J Haematol; 1990 Dec; 76 Suppl 2():14-8. PubMed ID: 2149045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of teicoplanin in the treatment of serious neonatal infections.
    Fanos V; Kacet N; Mosconi G
    Eur J Pediatr; 1997 Jun; 156(6):423-7. PubMed ID: 9208233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P; Aoun M; Meunier F
    Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are glycopeptides still appropriate and convenient for empiric use?
    Gonzalez-Ruiz A; Richardson J
    J Chemother; 2008 Oct; 20(5):531-41. PubMed ID: 19028614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spanish experience with teicoplanin.
    Fernández-Guerrero M; Gobernado M; Ariza J; Williams A
    Scand J Infect Dis Suppl; 1990; 72():38-44. PubMed ID: 2151066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Teicoplanin and Gram-positive coccus infections. Results of a multicenter study on 66 cases].
    Dureux JB; Canton P; Chavanet P; Chippaux C; Dupeyron JP; Estavoyer JM; Giorgi C; Jaeger A; Jehl F; Kazmierzack A
    Pathol Biol (Paris); 1987 May; 35(5):511-5. PubMed ID: 2956564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients.
    Testore GP; Uccella I; Sarrecchia C; Mattei A; Impagliazzo A; Sordillo P; Andreoni M
    J Chemother; 2000 Oct; 12(5):412-5. PubMed ID: 11128561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Teicoplanin in open fractures: a preliminary report.
    Hughes SP; Strachan E; Miles R; Williams AH
    Eur J Surg Suppl; 1992; (567):15-7. PubMed ID: 1381635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus.
    Pachon J; Prados D; Palomino J; Cantos A; Cisneros JM; Vaquero F
    J Antimicrob Chemother; 1996 Jan; 37(1):197-200. PubMed ID: 8647768
    [No Abstract]   [Full Text] [Related]  

  • 55. Teicoplanin in infections caused by methicillin-resistant staphylococci.
    Drabu YJ; Walsh B; Blakemore PH; Mehtar S
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.
    Leport C; Perronne C; Massip P; Canton P; Leclercq P; Bernard E; Lutun P; Garaud JJ; Vilde JL
    Antimicrob Agents Chemother; 1989 Jun; 33(6):871-6. PubMed ID: 2527483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM; Bryson HM
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
    Glupczynski Y; Lagast H; Van der Auwera P; Thys JP; Crokaert F; Yourassowsky E; Meunier-Carpentier F; Klastersky J; Kains JP; Serruys-Schoutens E
    Antimicrob Agents Chemother; 1986 Jan; 29(1):52-7. PubMed ID: 2942100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
    Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
    Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open study of teicoplanin in gram-positive infections.
    Walsh B; Drabu YJ; Mehtar S; Blakemore PH
    Int J Clin Pharmacol Res; 1988; 8(2):99-100. PubMed ID: 2967801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.